AGM Statement 2008

Evolutec Group plc
                    ("Evolutec" or "the Company")

          Results of Annual General Meeting, 10 April 2008

Evolutec is pleased to announce that all the resolutions proposed  at
its Annual General Meeting held today, 10 April 2008, were passed.

Evolutec will continue to seek an investment in a single,  profitable
UK or European un-quoted company  with an established trading  record
in the areas of technology, healthcare or the service sector.  It  is
anticipated that the  investment would  be an  active investment  and
will constitute a reverse takeover.

The  four  directors  of  Evolutec  have  considerable  expertise  in
mergers, acquisitions, the  sale of businesses  and the valuation  of
investments in the aforementioned sectors.   It is expected that  the
directors,  working   with  appropriate   advisers  including   Numis
Securities (the Company's  Nomad), will undertake  the due  diligence
for any proposed investment.

Under AIM Rule 15 the Company will continue as an investment  company
for 12 months during which time it is required to undertake a reverse
takeover or otherwise implement  its investment strategy. Should  the
Company fail to undertake either of the above, the Board  anticipates
that the shares  will be suspended  on 13 April  2009 or the  Company
will notify the market of any change.

Enquiries:

Dr David P Bloxham, Chairman                          07771 525 875
Mr Michael Meade, Numis Securities              0207 260 1000
Mr Oliver Cardigan, Numis Securities              0207 260 1000


Safe Harbour statement: this news release may contain forward-looking
statements that  reflect  the  current expectations  of  the  Company
regarding future events. Forward-looking statements involve risks and
uncertainties. Actual  events  could  differ  materially  from  those
projected herein  and depend  on a  number of  factors including  the
success of  the Company's  strategy,  the successful  integration  of
completed  mergers  and  acquisitions  and  achievement  of  expected
synergies from such transactions, and  the ability of the Company  to
identify and consummate suitable  strategic and business  combination
transactions.

---END OF MESSAGE---